Slayback Pharma LLC et al. vs Eye Therapies, LLC et al.

Termination Decision: Post-DI Settlement

Joint Stipulation To Change Due Date For Patent Owner's Response

Slayback Pharma and Eye Therapies LLC's Joint Motion to Terminate

Petitioner's Third Updated Exhibit List

Exhibit 1045 - Stipulation and Order of Dismissal from C.A. No. 21-16766-GC-RLS

Joint Stipulation to Change Due Date for Patent Owner's Response

Joint Stipulation to Change Due Date for Patent Owner's Response

Joint Stipulation To Change Due Date for Patent Owner's Response

Granting Petitioners Motions for Admission pro hac vice of Robert Frederickson III 37 C.F.R. § 42.10

Petitioner's Updated Mandatory Notices Pursuant to 37 C.F.R. section 42.8

Petitioner's Unopposed Motion for Pro Hac Vice Admission of Robert Frederickson III under 37 C.F.R. section 42.10(c)

Petitioner's Second Updated Exhibit List

Exhibit 1044

Petitioner's Updated Power of Attorney

Petitioner's Updated Mandatory Notices

Patent Owner's Amended Notice of Deposition of Paul A. Laskar, Ph.D.

Patent Owner's Notice of Deposition of Neal A. Sher, M.D., FACS

Patent Owner's Notice of Deposition of Paul A. Laskar, Ph.D.

Joint Stipulation to Change Due Date 1

Order Other Revised Joint Scheduling Order

Petitioner's Objections to Pre-Institution Exhibits

DECISION Granting Institution of Inter Partes Review 35 U.S.C. 314, 37 C.F.R. 42.4

JOINT SCHEDULING ORDER

Patent Owner's Sur-Reply Regarding Discretionary Denial

Petitioner Corrected Reply to Fintiv and 325(d) Issues in Preliminary Response

EXPUNGED

Petitioner First Updated Exhibit List

Sotera-type Stipulation to Limit Invalidity Contentions

Order: Conduct of the Proceeding - 37 CFR 42.5

Ex. 3001

Patent Owner's Preliminary Response

Patent Owner's Exhibit List

Joint Discovery Plan

Defs First Requests For Production Nos. 1-2

Scheduling Order

Order setting Initial Scheduling Conference

Slayback Paragraph-IV Letter

Complaint Against Slayback (DNJ)

Cantor 2006

US 6,982,079 ('079 patent)

US 5,021,416 ('416 patent)

Bausch Press Release re Redness

Alphagan (0.5%; 0.2%) Label (2001)

Visine-A Label

Alphagan P (0.15%; 0.1%) Label (2006)

Alphagan (0.2%) Approval Letter Sept. 1996

Drugs@FDA - Alphagan 0.5%

Drugs@FDA - Alphagan P 0.15%

Allergan Discontinues Alphagan (Sept. 2002)

Alphagan P (0.1%) Approval Letter (2005)

WO 2001-060347 A2

US 2010-0029,659 (Horn)

USPA 2010-0028,266 (Horn)

USPA 2010-0029,662 (Horn)

USPA 2010-0029,663 (Horn)

Compare 553 Patent and WO 347

Declaration of Christina J. Yang

Patent Owner's Updated Mandatory Notices

Patent Owner's Mandatory Notices

Patent Owner's Power of Attorney and Designation of Lead and Backup Counsel

Notice: Notice filing date accorded

Power of Attorney

Petition for IPR U.S. 9,259,425

U.S. Patent 9,259,425

Expert Declaration of Neal A. Sher, M.D.

Expert Declaration of Paul A. Laskar, Ph.D.

U.S. Patent 6,294,553

Walters 1991

Norden 2002

U.S. Patent 6,242,442

Alphagan Label(R) 1998

Federal Register 1988

Timmermans 1980

Griffith 2003

Wickberg 2001

Robin 1998

Lachkar 1998

Carlsson 2000

David 2001

Schuman 1997

Scruggs 2000

Pasquali 2013

Murphy 2007

Derick 1997

Burke 1995

David 1993

U.S. Patent Application Publication 2005/0244463

CDER Records 20613

Rahman 2010

U.S. Patent 6,562,873

Chien 1990

Burke 1996

U.S. Application 14/044,929

U.S. Application 12/928,749

U.S. Application 6/287,548

File Wrapper U.S. Application14/044,929 downloaded from PAIR

File Wrapper U.S. Application 12/928,749 downloaded from PAIR

Petitioner's Claim Listing for U.S. Patent 9,259,425